Citius Pharmaceuticals will spin off its I/ONTAK drug development and commercialization division, which has completed three phases of trials, into a separate public company. The company's other assets, including Mino-Lok, will remain in Citius. The deal is expected to close in the second half of 2022.
Warning BlackTerminal uses cookies in order to personalize and improve the usability of the service. If you do not want to use cookies, please change your browser settings. Accept